Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTL019 in Chinese children and young adults with relapsed/refractory B-cell ALL
CTR20211500Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of tisagenlecleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Novartis. Started Aug 2021; status: terminated.
02
Drugs
tisagenlecleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on CTR20211500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211500.